Standardized Infant NeuroDevelopmental Assessment (SINDA) in 0-24 Months Age in Turkey
NCT ID: NCT04889027
Last Updated: 2023-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2020-07-17
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of a Scale for Evaluation of Neuromotor Development of Infants
NCT05860166
The Relationship Between Developmental Level in Infancy and Preschool Motor Performance in Risky Infants
NCT06015347
Turkish Validity And Reliability Of The Hammersmith Infant Neurological Evaluation (Hine)
NCT04259177
Determination of Normal Measures of Optic Nerve Sheath Diameter in Children
NCT03178760
Use of Tools for Early Detection of Cerebral Palsy
NCT06531330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A clinical tool often used in predictions is a neurological examination. Various standard variants are available, such as the Hammersmith Infant Neurological Examination (HINE), Alberta Infant Motor Scale (AIMS).
The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome .This study aims to assess Turkish validity and reliability of Standardized Infant Neurodevelopmental Assessment and to spread its use for evaluation in early rehabilitation in our country.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standardized Infant NeuroDevelopmental Assessment
The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* discharged from neonatal intensive care unit;
* age between 0 - 24 months old (corrected age for premature infants);
* having a family acceptance for the participation
Exclusion Criteria
* musculoskeletal disorders,
* cyanotic congenital heart disease and
* mechanical dependency
1 Month
24 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ondokuz Mayıs University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nilay Comuk Balci
Pt, PhD, Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NILAY ÇÖMÜK BALCI
Role: PRINCIPAL_INVESTIGATOR
Ondokuz Mayıs University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nilay Çömük Balci
Samsun, Atakum, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020/017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.